Learn About Fibrolamellar Carcinoma

What is the definition of Fibrolamellar Carcinoma?
Many people with early FLC have no signs or symptoms of the condition. When present, symptoms are often nonspecific (i.e. abdominal pain, weight loss, malaise) and blamed on other, more common conditions. The exact underlying cause of FLC is poorly understood. Unlike other forms of liver cancer, FLC typically occurs in the absence of underlying liver inflammation or scarring; thus, specific risk factors for this condition remain unidentified.
Save information for later
Sign Up
What are the alternative names for Fibrolamellar Carcinoma?
  • Fibrolamellar carcinoma
  • Eosinophilic glassy cell hepatoma
  • Eosinophilic hepatocellular carcinoma with lamellar fibrosis
  • FHCC
  • FL-HCC
  • Fibrolamellar hepatocarcinoma
  • Fibrolamellar hepatocellular carcinoma
  • Fibrolamellar oncocytic hepatoma
  • Hepatocellular carcinoma with increased stromal fibrosis
  • Polygonal cell hepatocellular carcinoma with fibrous stroma
Who are the top Fibrolamellar Carcinoma Local Doctors?
Elite
Elite
 
 
 
 
Learn about our expert tiers
Learn more
Elite
What are the latest Fibrolamellar Carcinoma Clinical Trials?
A Pilot Study of a DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Fibrolamellar Hepatocellular Carcinoma
Summary: The primary objective of the trial is the safety and tolerability of administering a vaccine targeting the DNAJB1-PRKACA fusion kinase, in combination with nivolumab and ipilimumab in patients with unresectable or metastatic FLC and to assess the T-cell response.
Match to trials
Find the right clinical trials for you in under a minute
Get started
A Phase 1 Study of AGEN1181, an Fc-Engineered Anti-CTLA-4 Monoclonal Antibody as Monotherapy and in Combination With AGEN2034 (Balstilimab), an Anti-PD-1 Monoclonal Antibody, in Subjects With Advanced Cancer
Summary: This study is an open-label, Phase 1, multicenter study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamic (PD) profiles of a novel fragment crystallizable (Fc)-engineered immunoglobulin G1 anti-cytotoxic T-lymphocyte antigen 4 (anti-CTLA-4) human monoclonal antibody (botensilimab) monotherapy and in combination with an anti-programmed cell death protein-1 (PD-1) anti...
Who are the sources who wrote this article ?

Published Date: May 02, 2022
Published By: Genetic and Rare Diseases Informnation Center

What are the Latest Advances for Fibrolamellar Carcinoma?
Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): a multicentre, open-label, randomised, phase 3 trial.
Summary: Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): a multicentre, open-label, randomised, phase 3 trial.
Tired of the same old research?
Check Latest Advances